Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Study of Henagliflozin and Retagliptin
NCT02500485Phase 1Unknown
- Sponsor
- Hengrui
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of henagliflozin and retagliptin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SHR3824 at Day 18, Area Under the Plasma Concentration-Time Curve of SHR3824 at Day 18 and 3 more. Status: unknown.
02
Drugs
henagliflozinretagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02500485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500485.